FINGOLIMOD HYDROCHLORIDE Drug Patent Profile

Which patents cover Fingolimod Hydrochloride, and what generic alternatives are available?

Fingolimod Hydrochloride is a drug marketed by Accord Hlthcare, Alkem Labs Ltd, Apotex, Aurobindo Pharma Ltd, Biocon Ltd, Bionpharma, Chartwell Rx, Dr Reddys, Ezra Ventures, Glenmark Pharms Ltd, Hec Pharm Co Ltd, Hetero Labs Ltd V, Mylan, Prinston Inc, Sun Pharm, Teva Pharms Usa, and Zydus Pharms. and is included in eighteen NDAs.

The generic ingredient in FINGOLIMOD HYDROCHLORIDE is fingolimod hydrochloride. There are twenty-one drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the fingolimod hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Fingolimod Hydrochloride

A generic version of FINGOLIMOD HYDROCHLORIDE was approved as fingolimod hydrochloride by BIOCON LTD on December 4^th, 2019.

Summary for FINGOLIMOD HYDROCHLORIDE

US Patents:	0
Applicants:	17
NDAs:	18
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FINGOLIMOD HYDROCHLORIDE

Paragraph IV (Patent) Challenges for FINGOLIMOD HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GILENYA	Capsules	fingolimod hydrochloride	0.25 mg	022527	1	2018-07-19
GILENYA	Capsules	fingolimod hydrochloride	0.5 mg	022527	19	2014-09-22

US Patents and Regulatory Information for FINGOLIMOD HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Accord Hlthcare	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	207991-001	Oct 28, 2020	AB	RX	No	No
Zydus Pharms	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	207994-001	Oct 14, 2020	AB	RX	No	No
Chartwell Rx	FINGOLIMOD HYDROCHLORIDE	fingolimod hydrochloride	CAPSULE;ORAL	207971-001	Jun 29, 2020		DISCN	No	No

Investment Scenario and Fundamentals Analysis: Fingolimod Hydrochloride

Last updated: February 20, 2026

What Is Fingolimod Hydrochloride?

Fingolimod hydrochloride, marketed as Gilenya (by Novartis), is an oral sphingosine-1-phosphate receptor modulator approved for relapsing forms of multiple sclerosis (MS). It was first approved in the U.S. in 2010. The drug's mechanism involves trapping lymphocytes in lymph nodes, reducing CNS inflammation associated with MS.

Market Overview and Adoption

The global multiple sclerosis drugs market was valued at approximately USD 20 billion in 2022, with fingolimod accounting for roughly 15% sales share [1]. Growth is driven by rising MS prevalence, especially in North America and Europe, aging populations, and a shift toward oral therapies due to patient preference.

Market Penetration and Competition

Fingolimod faces competition from other oral MS agents, including:

• Dimethyl fumarate (Tecfidera)
• Teriflunomide (Aubagio)
• Siponimod (Mayzent)
• Ponesimod (R-CHOP, under development)

Despite competition, fingolimod maintains a leading position due to its established efficacy and safety profile.

Revenue and Sales Trends

In 2022, Novartis reported global sales of Gilenya at approximately USD 4.2 billion [2]. The growth rate from 2018 to 2022 averaged 4% annually. Patent expiry nearing in key markets (e.g., U.S. patent expiration in 2027) raises concerns over revenue erosion, emphasizing the importance of lifecycle management strategies.

Drivers and Risks in Investment

Growth Drivers

• Increasing global prevalence of MS
• Patient preference for oral therapies over injectable drugs
• Potential expansion into early or progressive MS indications
• Generic entry opportunities post-patent expiry

Risks and Challenges

• Patent expiration leading to generic competition
• Safety concerns such as cardiac arrhythmias and infections
• Regulatory challenges in expanding indications
• Market saturation in mature markets

Regulatory and Patent Landscape

Patent protection originally granted in multiple jurisdictions up to 2027, with patent extensions under consideration. Patent cliffs threaten revenue stability, requiring Novartis to innovate or seek new indications.

Clinical Development and Pipeline

Novartis is exploring fingolimod's efficacy in other autoimmune diseases, including psoriasis and inflammatory bowel disease. Early-phase trials are ongoing, but failure risks remain.

Investment Fundamentals

Key Metric	2022 Data	Notes
Global sales	USD 4.2 billion	Driven by MS treatment demand
Patent expiry	2027 (U.S.)	Patent cliffs imminent
Market share	Approximately 15% of the MS market	Competitive landscape tight
R&D investment	USD 1.2 billion (2022)	Focused on pipeline and new indications

Financial Impacts

Sales growth potential hinges on new indications and market penetration. Patent expiration could induce revenue decline unless offset by new formulations or indications.

Competitive Positioning

Fingolimod's older oral formulation provides a foundation but will face commoditization post-patent. The pipeline's success in expanding into new indications or developing next-generation molecules is critical for sustained valuation.

Key Takeaways

• Fingolimod hydrochloride is an established MS therapy with significant revenue in 2022.
• The upcoming patent expirations pose risks for revenue decline; strategic lifecycle management is essential.
• Market growth depends on expanding indications and patient access.
• Competitive landscape is intense, with several alternatives and emerging therapies.
• R&D efforts targeting new autoimmune indications offer potential upside.

FAQs

1. When will generic versions of fingolimod hydrochloride enter the market?
Generic entry is expected after patent expiry, scheduled for 2027 in the U.S. and possibly earlier in other jurisdictions with patent challenges.

2. What are the main side effects associated with fingolimod?
Risks include cardiac arrhythmias, infections, and macular edema. These safety concerns require monitoring during treatment initiation.

3. Are there opportunities for expanding fingolimod’s use?
Yes, clinical trials are investigating its efficacy in other autoimmune conditions, potentially broadening the market.

4. How does fingolimod compare to newer MS therapies?
Fingolimod has a well-established safety and efficacy profile but faces competition from newer agents with more favorable safety profiles or broader indications.

5. What strategic moves can enhance fingolimod’s future value?
Developing next-generation formulations, expanding indications, and portfolio diversification into other autoimmune diseases can mitigate patent risk and sustain revenues.

---

References

[1] Market Research Future. (2023). Multiple sclerosis drugs market report.
[2] Novartis Annual Report. (2022). Financial highlights and product sales.